• Categories:News
• Author:
• Origin:
• Time of issue:2021-02-05 15:19
• Views:

(Summary description)Original title: An article to read the development prospects of China's biologics market Source; Sina Pharmaceutical News By: E Drug Manager Biologics is one of the fastest growing sub-sectors in the pharmaceutical industry in recent years, and the global market size is expected to rise from $202 billion in 2016 to $326 billion in 2022, with a compound annual growth rate of 3%. China's market size grew from $62.7 billion in 2012 to $152.7 billion in 2016, with a compound annual growth rate of 24.9%.Frost & Sullivan expects China's biologics to maintain a compound annual growth rate of 16.4% from 2016 to 2021, reaching a market size of $326.9 billion by 2021. 1. Biologics will account for 30% in 2022 From the global drug sales ranking in the past few years, it can be seen that the proportion of biologics in the top 10 drugs in sales has been increasing year by year. 2017, seven are biomacromolecules, fully demonstrating the market's recognition of biologics. For the future market, Evaluate Pharma predicts that biologics will continue to maintain a strong market position, with the market share of biologics expected to rise from 25% ($202 billion) in 2016 to 30% ($326 billion) in 2022. Leading global pharmaceutical R&D companies are increasingly focused on biologic macromolecules, with more than 900 biologics in development for the world's 18 largest pharmaceutical companies alone. The investment of resources and funding in biologics R&D, continuous technological advances, and increasing awareness of disease have enabled pharmaceutical companies to continue to develop innovative biologics with superior efficacy and safety. The rapid growth of biologics is driven by three main factors: rapid expansion of indications, with the indications of biologics represented by antibody drugs rapidly expanding to include osteoporosis, multiple sclerosis, asthma, anti-infectives, cardiovascular and many other areas; accelerated progress of new drug launches, with the FDA approving a record high of 10 new antibody drugs in 2017; and the gradual expiration of patents for heavyweight biologics, with annual sales expected to combined $70-80 billion in biologics will lose patent protection in the next five years, which presents a significant opportunity for the development of biosimilars. Driven by increased healthcare spending, enhanced R&D capabilities, positive government policy changes and increased capital investment, China's biologics market has been growing rapidly over the past several years, outpacing the global market, and is expected to continue to grow strongly in the future. According to Frost & Sullivan, the market size of biologics in China grew from RMB 62.7 billion in 2012 to RMB 152.7 billion in 2016, with a compound annual growth rate of 24.9%. It is expected to grow at a CAGR of 16.4% from 2016 to 2021, reaching a market size of RMB 326.9 billion in 2021, presenting huge opportunities for Chinese biologics players. Meanwhile, antibody drugs, as an emerging segment of biologics, will see rapid growth, according to a Frost & Sullivan report, the market size of monoclonal antibodies in China increased from RMB 3.5 billion in 2012 to RMB 9.1 billion in 2016, with a CAGR of 26.8%. It is estimated to continue growing at a CAGR of 25.0% from 2016 to 2021, reaching a market size of RMB 27.6 billion in 2021. Recommendation: Our APIs and intermediates for the treatment of osteoporosis, multiple sclerosis, asthma, anti-infection, cardiovascular, tumor and other diseases are Anseritrapib, Vandetanib, Ospemifene, Minophosphate, etc. For more details, please browse our catalog or call us.